Clinical Study

Bbi-Dsp7888-102Ci- A Phase 1B, Multicenter, Open-Label Study Of Dsp-7888 Dosing Emulsion In Combination With Immune Checkpoint Inhibitors Nivolumab Or Atezolizumab In Adult Subjects With Advanced Solid Tumors

Posted Date: Jul 1, 2019

  • Investigator: Trisha Wise-Draper
  • Specialties: Cancer, Oncology
  • Type of Study: Drug

This study is a Phase 1b/2, open label, multicenter study for adult patients with solid tumors that evaluates the safety, tolerability, and identify a recommended intradermal dose of DSP 7888 in combination with Nivolumab or Pembrolizumab


To Be Eligible: Age 18 Or Older, Nonpregnant/Breastfeeding, Life Expectancy >3 Months, No Uncontrolled Current Illness


Tumors, Cancer, Advanced

For More Information:

Uccc Cancer Center

  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at or (513) 245-3417.